These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 35843439

  • 1. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
    Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D.
    Am J Kidney Dis; 2023 Feb; 81(2):145-155.e1. PubMed ID: 35843439
    [Abstract] [Full Text] [Related]

  • 2. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
    Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC, ILLUMINATE-A Collaborators.
    N Engl J Med; 2021 Apr 01; 384(13):1216-1226. PubMed ID: 33789010
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial.
    Frishberg Y, Hayes W, Shasha-Lavsky H, Sas DJ, Michael M, Sellier-Leclerc AL, Hogan J, Willey R, Gansner JM, Magen D.
    Front Pediatr; 2024 Apr 01; 12():1392644. PubMed ID: 39355649
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial.
    Hayes W, Sas DJ, Magen D, Shasha-Lavsky H, Michael M, Sellier-Leclerc AL, Hogan J, Ngo T, Sweetser MT, Gansner JM, McGregor TL, Frishberg Y.
    Pediatr Nephrol; 2023 Apr 01; 38(4):1075-1086. PubMed ID: 35913563
    [Abstract] [Full Text] [Related]

  • 5. Lumasiran: A Review in Primary Hyperoxaluria Type 1.
    Kang C.
    Drugs; 2024 Feb 01; 84(2):219-226. PubMed ID: 38252335
    [Abstract] [Full Text] [Related]

  • 6. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
    Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P, study collaborators.
    Clin J Am Soc Nephrol; 2021 Jul 01; 16(7):1025-1036. PubMed ID: 33985991
    [Abstract] [Full Text] [Related]

  • 7. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.
    Sas DJ, Magen D, Hayes W, Shasha-Lavsky H, Michael M, Schulte I, Sellier-Leclerc AL, Lu J, Seddighzadeh A, Habtemariam B, McGregor TL, Fujita KP, Frishberg Y, ILLUMINATE-B Workgroup.
    Genet Med; 2022 Mar 01; 24(3):654-662. PubMed ID: 34906487
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial.
    Saland JM, Lieske JC, Groothoff JW, Frishberg Y, Shasha-Lavsky H, Magen D, Moochhala SH, Simkova E, Coenen M, Hayes W, Hogan J, Sellier-Leclerc AL, Willey R, Gansner JM, Hulton SA.
    Kidney Int Rep; 2024 Jul 01; 9(7):2037-2046. PubMed ID: 39081738
    [Abstract] [Full Text] [Related]

  • 9. Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1.
    Hulton SA, Groothoff JW, Frishberg Y, Koren MJ, Overcash JS, Sellier-Leclerc AL, Shasha-Lavsky H, Saland JM, Hayes W, Magen D, Moochhala SH, Coenen M, Simkova E, Garrelfs SF, Sas DJ, Meliambro KA, Ngo T, Sweetser MT, Habtemariam BA, Gansner JM, McGregor TL, Lieske JC.
    Kidney Int Rep; 2022 Mar 01; 7(3):494-506. PubMed ID: 35257062
    [Abstract] [Full Text] [Related]

  • 10. Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1.
    Martin-Higueras C, Borghese L, Torres A, Fraga-Bilbao F, Santana-Estupiñán R, Stefanidis CJ, Tory K, Walli A, Gondra L, Kempf C, Gessner M, Habbig S, Eifler L, Schmitt CP, Rüdel B, Bartram MP, Beck BB, Hoppe B.
    Kidney Int Rep; 2024 Jan 01; 9(1):114-133. PubMed ID: 38312792
    [Abstract] [Full Text] [Related]

  • 11. Lumasiran for primary hyperoxaluria type 1: What we have learned?
    Gang X, Liu F, Mao J.
    Front Pediatr; 2022 Jan 01; 10():1052625. PubMed ID: 36704142
    [Abstract] [Full Text] [Related]

  • 12. Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study.
    Hoppe B, Pellikka PA, Dehmel B, Banos A, Lindner E, Herberg U.
    Nephrol Dial Transplant; 2021 Jul 23; 36(8):1464-1473. PubMed ID: 32810261
    [Abstract] [Full Text] [Related]

  • 13. The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants.
    Méaux MN, Sellier-Leclerc AL, Acquaviva-Bourdain C, Harambat J, Allard L, Bacchetta J.
    Pediatr Nephrol; 2022 Apr 23; 37(4):907-911. PubMed ID: 35015123
    [Abstract] [Full Text] [Related]

  • 14. Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1.
    Sas DJ, Mara K, Mehta RA, Seide BM, Banks CJ, Danese DS, McGregor TL, Lieske JC, Milliner DS.
    Pediatr Nephrol; 2024 Jan 23; 39(1):141-148. PubMed ID: 37458799
    [Abstract] [Full Text] [Related]

  • 15.
    Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Milliner DS, Harris PC, Sas DJ, Cogal AG, Lieske JC.
    ; 1993 Jan 23. PubMed ID: 20301460
    [Abstract] [Full Text] [Related]

  • 16. Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney function.
    Hillebrand P, Hoppe B.
    Pediatr Nephrol; 2020 Jul 23; 35(7):1227-1233. PubMed ID: 32274573
    [Abstract] [Full Text] [Related]

  • 17. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Milliner D, Hoppe B, Groothoff J.
    Urolithiasis; 2018 Aug 23; 46(4):313-323. PubMed ID: 28718073
    [Abstract] [Full Text] [Related]

  • 18. Lumasiran treatment in pediatric patients with PH1: real-world data within a compassionate use program in Italy.
    Taroni F, Peruzzi L, Longo G, Becherucci F, Malgieri G, D'Alessandro MM, Montini G.
    Clin Kidney J; 2024 May 23; 17(5):sfae090. PubMed ID: 38742209
    [Abstract] [Full Text] [Related]

  • 19. Case Report: Sustained Efficacy of Lumasiran at 18 Months in Primary Hyperoxaluria Type 1.
    Chiodini B, Tram N, Adams B, Hennaut E, Lolin K, Ismaili K.
    Front Pediatr; 2021 May 23; 9():791616. PubMed ID: 35071135
    [Abstract] [Full Text] [Related]

  • 20. Infantile Primary Hyperoxaluria Type 1 Treated With Lumasiran in Twin Males.
    Aldabek K, Grossman OK, Al-Omar O, Fox JA, Moritz ML.
    Cureus; 2022 Jan 23; 14(1):e21673. PubMed ID: 35237473
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.